

# Prescription Monitoring Program Advisory Council State of Louisiana

January 11, 2023

## MINUTES

A meeting of the Louisiana Prescription Monitoring Program (PMP) Advisory Council scheduled to meet on Wednesday, January 11, 2023 at the office of the Louisiana Board of Pharmacy, 3388 Brentwood Drive in Baton Rouge, Louisiana 70809, convened at 1:07 p.m. to consider the following:

### **A G E N D A**

1. Call to Order
2. Amendments to Council Roster
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Draft Minutes from Previous Meeting – October 12, 2022
6. Opportunity for Public Comment
7. Review of Program Operations
8. Review of Proposed Legislation
9. New Agenda Items Added During Meeting
10. Calendar Notes
11. Adjourn

**Advisory Council Representatives/Designees present:** Marty McKay (LABP) chaired the meeting. Also present were Jeff Gaude (NACDS), Vincent Culotta (LSBME), Traci Perry (LDH), Chad Pitre (LDAA), Lawrence Alexander (DEA), Chris Melancon (La. Senate-Chair H&W), Monique Calmes (LSBN), Jonathan Bowman (OAL), Lisa C. Bayhi (LANP), Lauren Bailey (LSMS), and Crystal Carter (LPA).

**Others present:** Joe Fontenot, Carlos Finalet, Reshmi Ravindranath, Carley Leach (all LABP), Michelle Olinde (James Drug Store), Patricia Wilton (LSBME), Robert Janot (OAL), Gillian Griffin (Taylor Porter), and Shelly Dupre (La. Alliance for Retail Pharmacies)

### **Amendments to Council Roster**

Mr. McKay reported the amendments to the Council Roster due to the change in leadership since the last Council meeting.

### **Call for Additional Agenda Items & Adoption of Agenda**

No additional agenda items introduced; agenda adopted.

### **Consideration of Draft Minutes from October 12, 2022 Meeting**

The October 12, 2022 meeting minutes was approved by consensus with no corrections.

### **Opportunity for Public Comment**

No public comments.

### **Review of Program Operations**

Joe Fontenot, Executive Director, presented statistical information regarding the program to the council.

**(Attachment 1).**

Mr. Fontenot explained there has been a continued decrease in the number of opioid and controlled dangerous substance prescriptions being dispensed and reported to the program in CY2022. He explained how the inclusion of new drugs of concern to the reporting requirement in January 2021 contributed to the increase in number of prescriptions transactions reported to the PMP. He also detailed how there has been a consistent, overall decrease in the number of controlled dangerous substance dispensations and opioid dispensations to Louisiana patients over time.

Hydrocodone bitartrate/acetaminophen (generic drug name) remains the number one controlled substance prescription dispensed to Louisiana patients in 2022. We continue to see a downward trend for Hydrocodone/APAP dispensing by number of prescriptions as well as dosage units to Louisiana residents over time.

## **PMP Advisory Council Meeting Minutes**

January 11, 2023

Page 2

---

Mr. Fontenot noted the therapeutic marijuana recommendations have increased significantly since August 2019. He explained the sharp increase in 2022 due to availability of raw product. Mr. Fontenot reported that the Board awarded the tenth therapeutic marijuana pharmacy permit after a competitive application process which ended in December 2022. A therapeutic marijuana satellite pharmacy permit has also been issued in LDH Region 1 and others are expected.

Mr. Fontenot reported that both the AWARxE© and Gateway© searches have increased significantly since 2016 with more searches being done via the PMP integration component, Gateway©. Mandatory use review and Clinical Alert components of PMP AWARxE© has increased participation in the PMP program. The LDH - Office of Public Health - Bureau of Community Preparedness grant which currently pays for the Gateway© integration license fees will expire in September of 2023. Additional funding for the upcoming year is being sought, possibly through CMS. Mr. Fontenot reported that discussions with the Ohio PMP program are ongoing with hopes of connecting with that state through PMP InterConnect. Mr. Fontenot noted that the amount of law enforcement, prosecutorial officials, and specialty court PMP requests have been erratic throughout the years showing decrease from when the program initially started.

### **Review of Proposed Legislation**

Mr. Fontenot and Mr. McKay reviewed the proposed draft legislation which would change the meeting frequency from quarterly to at least once annually and adds the exception for electronic meetings as detailed in the Legislative Proposal 2023 B ~ PMP Advisory Council Meetings Draft. Mr. Fontenot reminded the council that the proposed legislation was approved at the previous meeting of the council by consensus. The next step is to bring the draft proposal to the Board of Pharmacy's Regulation Revision Committee for their review on January 18 and then to the full Board on February 14. The approved proposal will then be brought before the legislature by representative Chris Turner in the upcoming session. Consensus was reached by members to distribute a PMP quarterly report to Council members even if the meeting requirements change. **(Attachment 2)**.

### **New Agenda Items Added During Meeting**

No new agenda items added.

### **Calendar Notes**

The Chair, Mr. Marty McKay, stated in accordance with the council's current preference for meeting dates, we have identified meeting dates for the Calendar Year 2023: April 12, July 12, and October 11.


### **Adjournment**

With no business remaining, the council meeting was adjourned at 1:51 p.m.

*I certify that the foregoing are true and accurate minutes.*

---


Joe Fontenot  
Executive Director  
Louisiana Board of Pharmacy

  
**LOUISIANA BOARD of PHARMACY**

**PRESCRIPTION MONITORING PROGRAM (PMP)**


ADVISORY COUNCIL MEETING - JANUARY 11, 2023

1



## PMP Reporting Comparisons - CDS


Reporting through 12/31/2022



3

## PMP Reporting Comparisons - Opioids


Reporting through 12/31/2022



4

## PMP Reporting Comparisons

Reporting through 12/31/2022



5

## 2022 Top 10 Controlled Substance Prescriptions Dispensed to Louisiana Patients by Generic Drug Name

<b>Generic Name</b>	<b>Patients</b>	<b>Prescriptions</b>	<b>Quantity</b>
HYDROCODONE BITARTRATE/ACETAMINOPHEN	567,542	1,514,731	78,270,891
DEXTROAMPHETAMINE SULF-SACCHARATE/AMPHETAMINE SULF-ASPARTATE	163,703	1,217,050	54,921,885
ALPRAZOLAM	169,215	896,717	46,290,811
TRAMADOL HCL	224,479	620,152	32,708,254
OXYCODONE HCL/ACETAMINOPHEN	184,599	568,096	34,623,841
CLONAZEPAM	88,468	536,636	27,387,437
ZOLPIDEM TARTRATE	80,038	531,622	17,019,592
LISDEXAMFETAMINE DIMESYLATE	80,522	474,114	14,348,547
LORAZEPAM	85,910	297,666	12,433,225
METHYLPHENIDATE HCL	51,680	272,524	12,254,777


6

## 2022 Top 10 Controlled Substance Prescriptions Dispensed to Louisiana Patients by Drug Label Name

<i>Label Name</i>	<i>Patients</i>	<i>Prescriptions</i>	<i>Quantity</i>
HYDROCODONE-ACETAMINOPHEN 10-325 MG TABLET	156,738	677,059	47,439,679
TRAMADOL HCL 50 MG TABLET	222,865	606,353	32,242,784
HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET	283,845	439,889	11,212,009
ZOLPIDEM TARTRATE 10 MG TABLET	54,409	376,845	12,102,956
ALPRAZOLAM 0.5 MG TABLET	80,289	375,960	18,587,991
HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET	187,555	371,583	14,529,806
DEXTROAMP-AMPHETAMIN 30 MG TAB	38,613	290,131	15,837,187
ALPRAZOLAM 1 MG TABLET	40,757	277,372	16,282,666
OXYCODONE-ACETAMINOPHEN 10-325 MG TAB	62,202	267,293	20,181,086
DEXTROAMP-AMPHETAMIN 20 MG TAB	45,351	266,013	14,881,521


7

## Hydrocodone /APAP Dispensing by Number of Prescriptions to Louisiana Residents



8

## Hydrocodone /APAP Dispensing by Number of Dosage Units to Louisiana Residents




9

## Louisiana Therapeutic Marijuana (TM) Dispensing

Reporting 01/01/2021 through 12/31/2022

**Total Prescription Count = 970,389**  
**Total Unique Patient Count = 75,449**  
**Total Unique Prescriber Count = 325**




10

## 2022 Louisiana Therapeutic Marijuana (TM) Dispensing

Reporting 01/01/2022 through 12/31/2022

Total Prescription Count = 792,099  
 Total Unique Patient Count = 65,526  
 Total Unique Prescriber Count = 291



11

### PMP User Stats for 2022Q4 (10/01/2022 - 12/31/2022)


PMP Healthcare Provider Role	Number of Providers Eligible for PMP Access (as of 12/31/2022)	Number of Providers with Active PMP Access Privileges (as of 12/31/2022)	Number of PMP Requests by Providers through AWARxE® During 2022Q4	Number of PMP Requests by Providers through Gateway® During 2022Q4
Physician (MD, DO)	13,518	9,327	503,408	5,560,493
Nurse Practitioner (APRN)	4,855	3,851	215,633	593,187
Dentist (DDS)	2,205	1,445	5,751	8,699
Physician Assistant (PA)	1,270	983	40,056	68,772
Optometrist (OD)	360	156	4	1
Podiatrist (DPM)	168	121	2,071	0
Medical Psychologist (MP)	98	88	9,105	9,124
Medical Intern/Resident	1,640	1,240	12,677	116,863
Prescriber's Delegate	N/A	3,794	186,552	0
Pharmacist (PST)	9,666	5,254	1,125,112	2,141,841
Pharmacist's Delegate	N/A	1,664	136,856	0
<b>Totals</b>	<b>33,780</b>	<b>27,923</b>	<b>2,237,225</b>	<b>8,498,980</b>

12



## Louisiana Prescriber & Pharmacist Searches through AWAxE® and Gateway®



(Ending 12/31/2022)



13

## PMP Statewide Integration Project through Gateway®

As of January 1, 2023, the Louisiana PMP is interoperable with 475 licensees (EHRs and pharmacy management systems) across the state. The 475 licensees represent more than 2,513 facilities in Louisiana and are responsible for 2,941,281 PMP requests in the month of December.



14


## PMP Interstate Data Sharing through PMP InterConnect®

As of December 31, 2022, the Louisiana PMP is sharing with 35 PMPs (1 federal district, 1 territory, 1 federal jurisdiction, and 32 states).

Alabama	Alaska	Arizona	Arkansas
Colorado	Connecticut	Delaware	D.C.
MHS-DOD	Florida	Georgia	Idaho
Indiana	Iowa	Kansas	Maine
Massachusetts	Michigan	Minnesota	Mississippi
Montana	Nevada	New Mexico	North Carolina
North Dakota	Oklahoma	Pennsylvania	Puerto Rico
Rhode Island	South Carolina	South Dakota	Tennessee
Texas	Virginia	West Virginia.	

15

## Law Enforcement, Prosecutorial Officials, and Specialty Court PMP Requests



16

1 HLS 23-  
2 Regular Session, 2023  
3 House Bill No. \_\_\_\_\_  
4 By Representative \_\_\_\_\_  
5

6 CONTROLLED DANGEROUS SUBSTANCES: Provides relative to the prescription  
7 monitoring program. (gov sig)  
8

9 AN ACT

10  
11 To amend and reenact R.S. 40:1005, relative to the prescription monitoring program advisory  
12 council; to provide for a change in the meeting occurrences; and to provide for meetings  
13 by electronic means.

14 Be it enacted by the Legislature of Louisiana:

15 Section 1. R.S. 40:1005 is hereby amended and reenacted to read as follows:

16 §1005. Prescription monitoring program advisory council

17 \* \* \*

18 B. The members of the advisory council shall serve at the pleasure of their  
19 respective appointing authorities, eleven of whom shall constitute a quorum for the  
20 transaction of all business. The members shall elect a chairman and vice chairman whose  
21 duties shall be established by the advisory council. The board shall fix a time and place  
22 for regular meetings of the advisory council, which shall meet at least ~~quarterly~~ once  
23 annually. The advisory council shall establish policies and procedures necessary to carry  
24 out its duties.

\* \* \*

25  
26 C. Notwithstanding any other provision of law to the contrary, the advisory  
27 council may conduct and its members may attend and participate in a meeting via  
28 electronic means provided:

29 (1) No later than twenty-four hours prior to a meeting conducted pursuant to  
30 the provisions of this Section, the advisory council shall provide for all of the  
31 following:

32 a. The notice and agenda for the meeting, which shall be posted on the  
33 website of the Louisiana Board of Pharmacy, emailed to any member of the  
34 public or the news media who requests notice of meetings of the public body, and  
35 widely distributed to every known news media outlet that broadcasts or publishes  
36 news within the geographic area within the jurisdiction of the Louisiana Board of  
37 Pharmacy.

38 b. Detailed information regarding how members of the public may  
39 participate in the meeting and submit comments regarding matters on the agenda,  
40 which information shall be posted on the website of the Louisiana Board of  
41 Pharmacy, emailed to any member of the public or the news media who requests  
42 notice of meetings of the public body, and widely distributed to every known  
43 news media outlet that broadcasts or publishes news within the geographic area  
44 within the jurisdiction of the Louisiana Board of Pharmacy.

45 (2) For each meeting conducted pursuant to this Section:

46 a. The advisory council shall provide a mechanism to receive public  
47 comment electronically both prior to and during the meeting.

48                    b. The advisory council shall properly identify and acknowledge all public  
49                    comments during the meeting and shall maintain those comments in its record of  
50                    the meeting.

51                    c. The presiding officer of the advisory council shall ensure that each  
52                    person participating in the meeting is properly identified.

53                    d. The presiding officer shall ensure that all parts of the meeting,  
54                    excluding any matter discussed in executive session, are clear and audible to all  
55                    participants in the meeting including the public.

56                    (3) For the purposes of this Section, the following words and phrases shall  
57                    have the following meanings:

58                    a. "Meeting via electronic means" shall mean a meeting occurring via  
59                    teleconference or video conference.

60                    b. "Teleconference" shall mean a method of communication which enables  
61                    persons in different locations to participate in a meeting and to hear and otherwise  
62                    communicate with each other.

63                    c. "Video conference" shall mean a method of communication which  
64                    enables persons in different locations to participate in a meeting and to see, hear,  
65                    and otherwise communicate with each other.

66                    D. The board shall seek, and the advisory council shall provide, information and  
67                    advice regarding the development and operation of the electronic monitoring system,  
68                    including but not limited to the following:

69                    (1) Which controlled substances should be monitored.

70                    (2) Which drugs of concern demonstrate a potential for abuse and should be  
71                    monitored.

72 (3) Design and implementation of educational courses identified in R.S.

73 40:1008.

74 (4) The methodology to be used for analysis and interpretation of prescription

75 monitoring information.

76 (5) Design and implementation of a program evaluation component.

77 (6) Identification of potential additional members to the advisory council.

78 Section 2. This Act shall become effective on signature by the governor or, if not signed

79 by the governor, upon expiration of the time for bills to become law without signature by

80 the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If

81 vetoed by the governor and subsequently approved by the legislature, this Act shall

82 become effective on the day following such approval.

83 [END]